Michael Barbella, Managing Editor03.23.23
Vicarious Surgical Inc.has appointed Victoria Carr-Brendel, Ph.D., to the Board of Directors as a replacement for Phil Liang, who resigned.
“On behalf of the board, I’d like to thank Phil for his critical guidance and expertise as Vicarious Surgical navigated the pathway from tech start-up to publicly traded surgical robotics company,” Board Chairman David Styka said. “We are thrilled to welcome Victoria to the Vicarious Surgical team. I’m confident that her decades of experience bringing innovative medical devices from concept to commercialization will prove to be a significant asset in contemplation of a market-ready system.”
Dr. Carr-Brendel has 24 years of medical device development experience leading R&D, new product development, divisional, and business development functions. She currently serves as the group vice president of Cochlear Implants at Sonova Group/president of Advanced Bionics, a Sonova company and a global leader in the treatment of severe-to-profound hearing loss. Before this, Dr. Carr-Brendel was CEO of JenaValve, a private company focused on developing transcatheter aortic valve repair systems to treat patients suffering from aortic valve disease. Between 2004 and 2015, she served in roles of increasing responsibility at Boston Scientific Corp., eventually overseeing the acquisition of Bayer’s Interventional radiology division in 2014.
Dr. Carr-Brendel earned a bachelor’s degree in biology from Monmouth College, a master of science degree in microbiology from Iowa State University, and a Ph.D. in microbiology and immunology from the University of Illinois at Chicago.
“I’m excited to join Vicarious Surgical at such a critical stage in their development efforts,” Dr. Carr-Brendel stated. “At this point in its trajectory, robotic assisted surgery possesses the potential to impact many more patients than are treated by today’s technology. With its unique value proposition, I believe Vicarious Surgical is well positioned to deliver a solution that disrupts the current market and delivers tremendous value to patients and providers.”
Founded in 2014, Vicarious Surgical is a next-generation robotics firm developing a technology to increase the efficiency of surgical procedures, improve patient outcomes, and reduce healthcare costs. The company’s surgical approach uses proprietary human-like surgical robots to transport surgeons inside the patient to perform minimally invasive surgery. The company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. Vicarious Surgical is headquartered in Waltham, Mass.
“On behalf of the board, I’d like to thank Phil for his critical guidance and expertise as Vicarious Surgical navigated the pathway from tech start-up to publicly traded surgical robotics company,” Board Chairman David Styka said. “We are thrilled to welcome Victoria to the Vicarious Surgical team. I’m confident that her decades of experience bringing innovative medical devices from concept to commercialization will prove to be a significant asset in contemplation of a market-ready system.”
Dr. Carr-Brendel has 24 years of medical device development experience leading R&D, new product development, divisional, and business development functions. She currently serves as the group vice president of Cochlear Implants at Sonova Group/president of Advanced Bionics, a Sonova company and a global leader in the treatment of severe-to-profound hearing loss. Before this, Dr. Carr-Brendel was CEO of JenaValve, a private company focused on developing transcatheter aortic valve repair systems to treat patients suffering from aortic valve disease. Between 2004 and 2015, she served in roles of increasing responsibility at Boston Scientific Corp., eventually overseeing the acquisition of Bayer’s Interventional radiology division in 2014.
Dr. Carr-Brendel earned a bachelor’s degree in biology from Monmouth College, a master of science degree in microbiology from Iowa State University, and a Ph.D. in microbiology and immunology from the University of Illinois at Chicago.
“I’m excited to join Vicarious Surgical at such a critical stage in their development efforts,” Dr. Carr-Brendel stated. “At this point in its trajectory, robotic assisted surgery possesses the potential to impact many more patients than are treated by today’s technology. With its unique value proposition, I believe Vicarious Surgical is well positioned to deliver a solution that disrupts the current market and delivers tremendous value to patients and providers.”
Founded in 2014, Vicarious Surgical is a next-generation robotics firm developing a technology to increase the efficiency of surgical procedures, improve patient outcomes, and reduce healthcare costs. The company’s surgical approach uses proprietary human-like surgical robots to transport surgeons inside the patient to perform minimally invasive surgery. The company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. Vicarious Surgical is headquartered in Waltham, Mass.